06 aprile 2021 13:02 Fonte: Adnkronos #salute-e-benessere Simple, Non-Invasive Blood Test Poses No Risk to Pregnant Woman and Fetus; Significantly Safer, More Comprehensive and More Inclusive Compared to Invasive Tissue Sampling Test Intended for All Pregnant Women, Not Just High-Risk Categories, at 10-14 Weeks of Pregnancy; Earlier Administration Potentially Leading to Higher Confidence and More Individualized Care Achievement Follows ARCEDI's Prior Non-Invasive Pregnancy Testing Innovations, Including Being the First Company to Identify Extravillous Trophoblasts as the Fetal Cell Types Circulating Within the Maternal Bloodstream VEJLE, Denmark, April 6, 2021 /PRNewswire/ -- ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced the launch of EVITA TEST COMPLETE™ (EVITA), the first prenatal genetic blood test to identify and isolate fetal cells in maternal blood. EVITA provides a complete overview of all 22 chromosome pairs and sex chromosomes of the fetus to identify the presence of a number of serious chromosome abnormalities that can cause syndromes, and it can also identify the sex of the baby from as early as week 12 of pregnancy. EVITA, developed through a 16-year-long public-private research collaboration with Denmark-based Aarhus University Hospital, is intended for use by all pregnant women via a simple blood-draw, not just women who fall into high-risk categories like with currently available gold-standard tests. EVITA will first become available to private fertility clinics in Denmark, beginning with the AAGAARD Fertility Clinic, Aarhus (a member of Virtus Health) on April 6, 2021.